Results 31 to 40 of about 83,236 (262)
Expression of CTLA‐4 by Human Monocytes [PDF]
Cytotoxic T lymphocyte‐associated molecule‐4 (CTLA‐4) is a receptor present on T cells that plays a critical role in the downregulation of antigen‐activated immune responses. CTLA‐4 interacts with the ligands CD80 and CD86 on antigen‐presenting cells (APC), and also directs the assembly of inhibitory signalling complexes that lead to quiescence or ...
X-B, Wang +5 more
openaire +2 more sources
The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Background Immune checkpoint inhibitor (ICPI) can augment the anti-tumour response by blocking negative immunoregulators with monoclonal antibodies. The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody is the first ICPI which has shown ...
Shashuang Zhang +4 more
doaj +1 more source
CTLA-4 trafficking and surface expression [PDF]
The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid ...
Elke, Valk +2 more
openaire +2 more sources
برهمکنش های مولکولی بین CTLA-4 و CD80/CD86 در تنظیم پاسخ های ایمنی: مقاله مروری [PDF]
یکی از اصلی ترین مکانیسم های تنظیم پاسخ های ایمنی برهم کنش متقابل CTLA-4 و CD80/CD86 است. CTLA-4 نوعی رسپتور مهاری و دارای لیگاندهای CD80/CD86 و مشترک با گیرنده کمک محرک CD28 است. CTLA-4 طی فرآیندی به نام ترانس اندوسیتوزیس این لیگاندها را اندوسیتوز کرده
زهرا درویش خلیل آبادی +2 more
doaj +1 more source
Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
Autoimmune lymphoproliferative syndrome (ALPS) is an inherited non-malignant and non-infectious lymphoproliferative syndrome caused by mutations in genes affecting the extrinsic apoptotic pathway (FAS, FASL, CASP10).
Laura Gámez-Díaz, Bodo Grimbacher
doaj +1 more source
ALPSOY, ERKAN/0000-0001-7049-0170; uzun, soner/0000-0001-7059-5474; gunasti topal, suhan/0000-0003-0467-5884;
Bacanli, Ali +6 more
openaire +2 more sources
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
CTLA-4: Not All Costimulation Is Stimulatory [PDF]
To activate a T cell, it was widely accepted, even in the 1960s, that there had to be a “signal one,” namely, receptor recognition of a foreign Ag. That fact did not make it less exciting when, in the early 1980s, Abs to the TCR were generated and the genes that encode it identified ([1][1 ...
Hugh, Auchincloss, Laurence A, Turka
openaire +2 more sources
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a crucial immune checkpoint that is constitutively expressed in regulatory T (Treg) cells. Following T-cell activation, CTLA-4 is rapidly mobilized from its intracellular vesicle pool to the cell surface to ...
Laura Gámez-Díaz +2 more
doaj +1 more source

